Language: Spanish
References: 221
Page: 31-59
PDF size: 409.50 Kb.

Text Extraction

no abstract

REFERENCES

1. Recommendations for the Use of Intravenous Antibiotic Prophylaxis in Primary Total Joint Arthroplasty [Accessed 2013]. Available in: http://www.aaos.org/about/papers/advistmt/1027.asp.

2. Prokuski L: Prophylactic antibiotics in orthopaedic surgery. J Am Acad Orthop Surg. 2008; 16(5): 283-93.

3. Bratzler DW, Houck PM: Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis. 2004; 38(12): 1706-15.

4. Van Kasteren ME, Mannien J, Ott A, Kullberg BJ, de Boer AS, Gyssens IC: Antibiotic prophylaxis and the risk of surgical site infections following total hip arthroplasty: timely administration is the most important factor. Clin Infect Dis. 2007; 44(7): 921-7.

5. Classen DC, Evans RS, Pestotnik SL, Horn SD, Menlove RL, Burke JP: The timing of prophylactic administration of antibiotics and the risk of surgical-wound infection. N Engl J Med. 1992; 326(5): 281-6.

6. Bratzler DW, Houck PM: Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Am J Surg. 2005; 189(4): 395-404.

7. Galandiuk S, Polk HC, Jr, Jagelman DG, Fazio VW: Re-emphasis of priorities in surgical antibiotic prophylaxis. Surg Gynecol Obstet. 1989; 169(3): 219-222.

8. Hawn MT, Richman JS, Vick CC, et al: Timing of surgical antibiotic prophylaxis and the risk of surgical site infection. JAMA Surg. 2013; 148(7): 649-657.

9. Weber WP, Marti WR, Zwahlen M, et al: The timing of surgical antimicrobial prophylaxis. Ann Surg. 2008; 247(6): 918-926.

10. Steinberg JP, Braun BI, Hellinger WC, et al: Timing of antimicrobial prophylaxis and the risk of surgical site infections: results from the Trial to Reduce Antimicrobial Prophylaxis Errors. Ann Surg. 2009; 250(1): 10-16.

11. Johnson DP: Antibiotic prophylaxis with cefuroxime in arthroplasty of the knee. J Bone Joint Surg Br. 1987; 69(5): 787-789.

12. Friedman RJ, Friedrich LV, White RL, Kays MB, Brundage DM, Graham J: Antibiotic prophylaxis and tourniquet inflation in total knee arthroplasty. Clin Orthop Relat Res. 1990(260): 17-23.

13. Soriano A, Bori G, Garcia-Ramiro S, et al: Timing of antibiotic prophylaxis for primary total knee arthroplasty performed during ischemia. Clin Infect Dis. 2008; 46(7): 1009-1014.

14. A WD, Robertsson O, Stefansdottir A, Gustafson P, Lidgren L: Timing of preoperative antibiotics for knee arthroplasties: Improving the roIAUnes in Sweden. Patient Saf Surg. 2011; 5: 22.

15. Neu HC: Cephalosporin antibiotics as applied in surgery of bones and joints. Clin Orthop Relat Res. 1984(190): 50-64.

16. Oishi CS, Carrion WV, Hoaglund FT: Use of parenteral prophylactic antibiotics in clean orthopaedic surgery. A review of the literature. Clin Orthop Relat Res. 1993(296): 249-255.

17. Schurman DJ, Hirshman HP, Kajiyama G, Moser K, Burton DS: Cefazolin concentrations in bone and synovial fluid. J Bone Joint Surg Am. 1978; 60(3): 359-362.

18. Forse RA, Karam B, MacLean LD, Christou NV: Antibiotic prophylaxis for surgery in morbidly obese patients. Surgery. 1989; 106(4): 750-756; discussion 756-757.

19. Sodhi M, Axtell SS, Callahan J, Shekar R: Is it safe to use carbapenems in patients with a history of allergy to penicillin? J Antimicrob Chemother. 2004; 54(6): 1155-1157.

20. Hill C, Flamant R, Mazas F, Evrard J: Prophylactic cefazolin versus placebo in total hip replacement. Report of a multicentre double-blind randomised trial. Lancet. 1981; 1(8224): 795-796.

21. Tyllianakis ME, Karageorgos A, Marangos MN, Saridis AG, Lambiris EE: Antibiotic prophylaxis in primary hip and knee arthroplasty: comparison between cefuroxime and two specific antistaphylococcal agents. J Arthroplasty. 2010; 25(7): 1078-1082.

22. Mauerhan DR, Nelson CL, Smith DL, et al: Prophylaxis against infection in total joint arthroplasty. One day of cefuroxime compared with three days of cefazolin. J Bone Joint Surg Am. 1994; 76(1): 39-45.

23. Stefansdottir A, Johansson D, Knutson K, Lidgren L, Robertsson O: Microbiology of the infected knee arthroplasty: report from the Swedish Knee Arthroplasty Register on 426 surgically revised cases. Scand J Infect Dis. 2009; 41(11-12): 831-840.

24. Enzler MJ, Berbari E, Osmon DR: Antimicrobial prophylaxis in adults. Mayo Clin Proc. 2011; 86(7): 686-701.

25. Wilson W, Taubert KA, Gewitz M, et al: Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2007; 116(15): 1736-1754.

26. Eagle KA, Guyton RA, Davidoff R, et al: ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation. 2004; 110(14): e340-437.

27. Edwards FH, Engelman RM, Houck P, Shahian DM, Bridges CR: The Society of Thoracic Surgeons Practice Guideline Series: Antibiotic prophylaxis in cardiac surgery, part I: Duration. Ann Thorac Surg. 2006; 81(1): 397-404.

28. Haydon TP, Presneill JJ, Robertson MS: Antibiotic prophylaxis for cardiac surgery in Australia. Med J Aust. 2010; 192(3): 141-143.

29. Mollan RA, Haddock M, Webb CH: Teicoplanin versus cephamandole for antimicrobial prophylaxis in prosthetic joint implant surgery: (preliminary results). Eur J Surg Suppl. 1992(567): 19-21.

30. Lazzarini L, Pellizzer G, Stecca C, Viola R, de Lalla F: Postoperative infections following total knee replacement: an epidemiological study. J Chemother. 2001; 13(2): 182-187.

31. Periti P, PannIAU F, Della Cuna GR, et al: Combination chemotherapy with cyclophosphamide, fluorouracil, and either epirubicin or mitoxantrone: a comparative randomized multicenter study in metastatic breast carcinoma. Cancer Invest. 1991; 9(3): 249-255.

32. Periti P, Stringa G, Mini E: Comparative multicenter trial of teicoplanin versus cefazolin for antimicrobial prophylaxis in prosthetic joint implant surgery. Italian Study Group for Antimicrobial Prophylaxis in Orthopedic Surgery. Eur J Clin Microbiol Infect Dis. 1999; 18(2): 113-119.

33. Brogden RN, Peters DH. Teicoplanin: A reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeIAUc efficacy. Drugs. 1994; 47(5): 823-854.

34. Wood MJ. The comparative efficacy and safety of teicoplanin and vancomycin. J Antimicrob Chemother. 1996; 37(2): 209-222.

35. Wilson AP: Antibiotic prophylaxis in cardiac surgery. J Antimicrob Chemother. 1988; 21(5): 522-524.

36. Darley ES, MacGowan AP: Antibiotic treatment of Gram-positive bone and joint infections. J Antimicrob Chemother. 2004; 53(6): 928-935.

37. Dash CH. Penicillin allergy and the cephalosporins. J Antimicrob Chemother. 1975; 1(3 Suppl): 107-118.

38. Petz LD: Immunologic cross-reactivity between penicillins and cephalosporins: a review. J Infect Dis. 1978; 137 Suppl: S74-S79.

39. Kelkar PS, Li JT: Cephalosporin allergy. N Engl J Med. 2001; 345(11): 804-809.

40. Saxon A, Beall GN, Rohr AS, Adelman DC: Immediate hypersensitivity reactions to beta-lactam antibiotics. Ann Intern Med. 1987; 107(2): 204-215.

41. Pichichero ME: Use of selected cephalosporins in penicillin-allergic patients: a paradigm shift. Diagn Microbiol Infect Dis. 2007; 57(3 Suppl): 13S-18S.

42. Pichichero ME, Casey JR: Safe use of selected cephalosporins in penicillin-allergic patients: a meta-analysis. Otolaryngol Head Neck Surg. 2007; 136(3): 340-347.

43. Audicana M, Bernaola G, Urrutia I, et al: Allergic reactions to betalactams: studies in a group of patients allergic to penicillin and evaluation of cross-reactivity with cephalosporin. Allergy. 1994; 49(2): 108-113.

44. Solensky R, Earl HS, Gruchalla RS: Lack of penicillin resensitization in patients with a history of penicillin allergy after receiving repeated penicillin courses. Arch Intern Med. 2002; 162(7): 822-826.

45. Campagna JD, Bond MC, Schabelman E, Hayes BD: The use of cephalosporins in penicillin-allergic patients: a literature review. J Emerg Med. 2012; 42(5): 612-620.

46. DePestel DD, Benninger MS, Danziger L, et al: Cephalosporin use in treatment of patients with penicillin allergies. J Am Pharm Assoc. 2008; 48(4): 530-540.

47. Platt R: Adverse effects of third-generation cephalosporins. J Antimicrob Chemother. 1982; 10 Suppl C: 135-140.

48. Goodman EJ, Morgan MJ, Johnson PA, Nichols BA, Denk N, Gold BB: Cephalosporins can be given to penicillin-allergic patients who do not exhibit an anaphylactic response. J Clin Anesth. 2001; 13(8): 561-564.

49. Apter AJ, Kinman JL, Bilker WB, et al: Is there cross-reactivity between penicillins and cephalosporins? Am J Med. 2006; 119(4): 354 e311-359.

50. Park MA, Koch CA, Klemawesch P, Joshi A, Li JT: Increased adverse drug reactions to cephalosporins in penicillin allergy patients with positive penicillin skin test. Int Arch Allergy Immunol. 2010; 153(3): 268-273.

51. Advisory statement. Recommendations for the use of intravenous antibiotic prophylaxis in primary total joint arthroplasty. AAOS [Accessed 2013]. Available in: http://www.aaos.org/about/papers/advistmt/1027.asp

52. Muto CA, Jernigan JA, Ostrowsky BE, et al: SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol. 2003; 24(5): 362-386.

53. Cantoni L, Glauser MP, Bille J: Comparative efficacy of daptomycin, vancomycin, and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role of test conditions in this determination. Antimicrob Agents Chemother. 1990; 34(12): 2348-2353.

54. Patel M, Kumar RA, Stamm AM, Hoesley CJ, Moser SA, Waites KB: USA300 genotype community-associated methicillin-resistant Staphylococcus aureus as a cause of surgical site infections. J Clin Microbiol. 2007; 45(10): 3431-3433.

55. Manian FA, Griesnauer S: Community-associated methicillin-resistant Staphylococcus aureus (MRSA) is replacing traditional health care-associated MRSA strains in surgical-site infections among inpatients. Clin Infect Dis. 2008; 47(3): 434-435.

56. Recommendations for preventing the spread of vancomycin resistance: Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep. 1995; 44(RR-12): 1-13.

57. Hiramatsu K, Aritaka N, Hanaki H, et al: Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet. 1997; 350(9092): 1670-1673.

58. Michel M, Gutmann L: Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: therapeIAUc realities and possibilities. Lancet. 1997; 349(9069): 1901-1906.

59. Fulkerson E, Valle CJ, Wise B, Walsh M, Preston C, Di Cesare PE: Antibiotic susceptibility of bacteria infecting total joint arthroplasty sites. J Bone Joint Surg Am. 2006; 88(6): 1231-1237.

60. UK Health protection agency: Surgical Site Infection surveillance service. Protocol for surveillance of surgical site infection. Available in: http://www.hpa.org/uk/we/HPAwebFile/HPAweb_C/1194947388966, Accessed 2013.

61. Meehan J, Jamali AA, Nguyen H: Prophylactic antibiotics in hip and knee arthroplasty. J Bone Joint Surg Am. 2009; 91(10): 2480-2490.

62. Wiesel BB, Esterhai JL: Prophylaxis of musculoskeletal infections. In: J C, JT M, eds. Musculosketal Infections. New York: Marcel Dekker; 2003: 115-129.

63. Merrer J, Desbouchages L, Serazin V, Razafimamonjy J, Pauthier F, Leneveu M: Comparison of roIAUne prophylaxis with vancomycin or cefazolin for femoral neck fracture surgery: microbiological and clinical outcomes. Infect Control Hosp Epidemiol. 2006; 27(12): 1366-1371.

64. Cranny G, Elliott R, Weatherly H, et al: A systematic review and economic model of switching from non-glycopeptide to glycopeptide antibiotic prophylaxis for surgery. Health Technol Assess. 2008; 12(1): iii-iv, xi-xii, 1-147.

65. Bolon MK, Morlote M, Weber SG, Koplan B, Carmeli Y, Wright SB: Glycopeptides are no more effective than beta-lactam agents for prevention of surgical site infection after cardiac surgery: a meta-analysis. Clin Infect Dis. 2004; 38(10): 1357-1363.

66. ManGram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR: Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol. 1999; 20(4): 250-278; quiz 279-280.

67. Tacconelli E, Cataldo MA, Albanese A, et al: Vancomycin versus cefazolin prophylaxis for cerebrospinal shunt placement in a hospital with a high prevalence of meticillin-resistant Staphylococcus aureus. J Hosp Infect. 2008; 69(4): 337-344.

68. Finkelstein R, Rabino G, Mashiah T, et al: Vancomycin versus cefazolin prophylaxis for cardiac surgery in the setting of a high prevalence of methicillin-resistant staphylococcal infections. J Thorac Cardiovasc Surg. 2002; 123(2): 326-332.

69. Garey KW, Lai D, Dao-Tran TK, Gentry LO, Hwang LY, Davis BR: Interrupted time series analysis of vancomycin compared to cefuroxime for surgical prophylaxis in patients undergoing cardiac surgery. Antimicrob Agents Chemother. 2008; 52(2): 446-451.

70. Spelman D, Harrington G, Russo P, Wesselingh S: Clinical, microbiological, and economic benefit of a change in antibiotic prophylaxis for cardiac surgery. Infect Control Hosp Epidemiol. 2002; 23(7): 402-404.

71. Smith EB, Wynne R, Joshi A, Liu H, Good RP: Is it time to include vancomycin for roIAUne perioperative antibiotic prophylaxis in total joint arthroplasty patients? J Arthroplasty. 2012; 27(8 Suppl): 55-60.

72. Bull AL, Worth LJ, Richards MJ: Impact of vancomycin surgical antibiotic prophylaxis on the development of methicillin-sensitive Staphylococcus aureus surgical site infections: report from Australian Surveillance Data (VICNISS). Ann Surg. 2012; 256(6): 1089-1092.

73. Miller LG, McKinnell JA, Vollmer ME, Spellberg B: Impact of methicillin-resistant Staphylococcus aureus prevalence among S. aureus isolates on surgical site infection risk after coronary artery bypass surgery. Infect Control Hosp Epidemiol. 2011; 32(4): 342-350.

74. Zanetti G, Giardina R, Platt R: Intraoperative redosing of cefazolin and risk for surgical site infection in cardiac surgery. Emerg Infect Dis. 2001; 7(5): 828-831.

75. Zanetti G, Goldie SJ, Platt R: Clinical consequences and cost of limiting use of vancomycin for perioperative prophylaxis: example of coronary artery bypass surgery. Emerg Infect Dis. 2001; 7(5): 820-827.

76. Muralidhar B, Anwar SM, Handa AI, Peto TE, Bowler IC: Prevalence of MRSA in emergency and elective patients admitted to a vascular surgical unit: implications for antibiotic prophylaxis. Eur J Vasc Endovasc Surg. 2006; 32(4): 402-407.

77. Gemmell CG, Edwards DI, Fraise AP, Gould FK, Ridgway GL, Warren RE: Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother. 2006; 57(4): 589-608.

78. Elliott RA, Weatherly HL, Hawkins NS, et al: An economic model for the prevention of MRSA infections after surgery: non-glycopeptide or glycopeptide antibiotic prophylaxis? Eur J Health Econ. 2010; 11(1): 57-66.

79. Walsh EE, Greene L, Kirshner R: Sustained reduction in methicillin-resistant Staphylococcus aureus wound infections after cardiothoracic surgery. Arch Intern Med. 2011; 171(1): 68-73.

80. Dhadwal K, Al-Ruzzeh S, Athanasiou T, et al: Comparison of clinical and economic outcomes of two antibiotic prophylaxis regimens for sternal wound infection in high-risk patients following coronary artery bypass grafting surgery: a prospective randomised double-blind controlled trial. Heart. 2007; 93(9): 1126-1133.

81. Patrick S, James C, Ali A, Lawson S, Mary E, Modak A: Vascular surgical antibiotic prophylaxis study (VSAPS). Vasc Endovascular Surg. 2010; 44(7): 521-528.

82. Sewick A, Makani A, Wu C, O’Donnell J, Baldwin KD, Lee GC: Does dual antibiotic prophylaxis better prevent surgical site infections in total joint arthroplasty? Clin Orthop Relat Res. 2012; 470(10): 2702-2707.

83. Ritter MA, Barzilauskas CD, Faris PM, Keating EM: Vancomycin prophylaxis and elective total joint arthroplasty. Orthopedics. 1989; 12(10): 1333-1336.

84. Cruess RL, Bickel WS, von Kessler KL: Infections in total hips secondary to a primary source elsewhere. Clin Orthop Relat Res. 1975(106): 99-101.

85. Hall AJ: Late infection about a total knee prosthesis. Report of a case secondary to urinary tract infection. J Bone Joint Surg Br. 1974; 56(1): 144-147.

86. David TS, Vrahas MS: Perioperative lower urinary tract infections and deep sepsis in patients undergoing total joint arthroplasty. J Am Acad Orthop Surg. 2000; 8(1): 66-74.

87. Ritter MA, Fechtman RW: Urinary tract sequelae: possible influence on joint infections following total joint replacement. Orthopedics. 1987; 10(3): 467-469.

88. Wymenga AB, van Horn JR, Theeuwes A, Muytjens HL, Slooff TJ: Perioperative factors associated with septic arthritis after arthroplasty. Prospective multicenter study of 362 knee and 2,651 hip operations. Acta Orthop Scand. 1992; 63(6): 665-671.

89. Glynn MK, Sheehan JM: The significance of asymptomatic bacteriuria in patients undergoing hip/knee arthroplasty. Clin Orthop Relat Res. 1984(185): 151-154.

90. Waterhouse N, Beaumont AR, Murray K, Staniforth P, Stone MH: Urinary retention after total hip replacement. A prospective study. J Bone Joint Surg Br. 1987; 69(1): 64-66.

91. Walton JK, Robinson RG: An analysis of a male population having total hip replacement with regard to urological assessment and post-operative urinary retention. Br J Urol. 1982; 54(5): 519-521.

92. Drekonja DM, Rector TS, Cutting A, Johnson JR: Urinary tract infection in male veterans: treatment patterns and outcomes. JAMA Intern Med. 2013; 173(1): 62-68.

93. Irvine R, Johnson BL, Jr, Amstutz HC: The relationship of genitourinary tract procedures and deep sepsis after total hip replacements. Surg Gynecol Obstet. 1974; 139(5): 701-706.

94. Garibaldi RA, Burke JP, Dickman ML, Smith CB: Factors predisposing to bacteriuria during indwelling urethral catheterization. N Engl J Med. 1974; 291(5): 215-219.

95. Kunin CM, McCormack RC: Prevention of catheter-induced urinary-tract infections by sterile closed drainage. N Engl J Med. 1966; 274(21): 1155-1161.

96. Jerry GJ, Jr, Rand JA, Ilstrup D: Old sepsis prior to total knee arthroplasty. Clin Orthop Relat Res. 1988(236): 135-140.

97. Lee GC, Pagnano MW, Hanssen AD: Total knee arthroplasty after prior bone or joint sepsis about the knee. Clin Orthop Relat Res. 2002(404): 226-231.

98. Larson AN, Hanssen AD, Cass JR: Does prior infection alter the outcome of TKA after tibial plateau fracture? Clin Orthop Relat Res. 2009; 467(7): 1793-1799.

99. Michelson JD, Lotke PA, Steinberg ME: Urinary-bladder management after total joint-replacement surgery. N Engl J Med. 1988; 319(6): 321-326.

100. Martinez OV, Civetta JM, Anderson K, Roger S, Murtha M, Malinin TI: Bacteriuria in the catheterized surgical intensive care patient. Crit Care Med. 1986; 14(3): 188-191.

101. Schaeffer AJ: Catheter-associated bacteriuria. Urol Clin North Am. 1986; 13(4): 735-747.

102. Skelly JM, Guyatt GH, Kalbfleisch R, Singer J, Winter L: Management of urinary retention after surgical repair of hip fracture. CMAJ. 1992; 146(7): 1185-1189.

103. Donovan TL, Gordon RO, Nagel DA: Urinary infections in total hip arthroplasty. Influences of prophylactic cephalosporins and catheterization. J Bone Joint Surg Am. 1976; 58(8): 1134-1137.

104. Fitzgerald RH, Jr, Nolan DR, Ilstrup DM, Van Scoy RE, Washington JA, 2nd, Coventry MB: Deep wound sepsis following total hip arthroplasty. J Bone Joint Surg Am. 1977; 59(7): 847-855.

105. Surin VV, Sundholm K, Backman L: Infection after total hip replacement. With special reference to a discharge from the wound. J Bone Joint Surg Br. 1983; 65(4): 412-418.

106. Felippe WA, Werneck GL, Santoro-Lopes G: Surgical site infection among women discharged with a drain in situ after breast cancer surgery. World J Surg. 2007; 31(12): 2293-2299; discussion 2300-2291.

107. Lanier ST, Wang ED, Chen JJ, et al: The effect of acellular dermal matrix use on complication rates in tissue expander/implant breast reconstruction. Ann Plast Surg. 2010; 64(5): 674-678.

108. Sorensen AI, Sorensen TS: Bacterial growth on suction drain tips. Prospective study of 489 clean orthopedic operations. Acta Orthop Scand. 1991; 62(5): 451-454.

109. van den Brand IC, Castelein RM: Total joint arthroplasty and incidence of postoperative bacteriuria with an indwelling catheter or intermittent catheterization with one-dose antibiotic prophylaxis: a prospective randomized trial. J Arthroplasty. 2001; 16(7): 850-855.

110. Oishi CS, Williams VJ, Hanson PB, Schneider JE, Colwell CW, Jr, Walker RH: Perioperative bladder management after primary total hip arthroplasty. J Arthroplasty. 1995; 10(6): 732-736.

111. Koulouvaris P, Sculco P, Finerty E, Sculco T, Sharrock NE: Relationship between perioperative urinary tract infection and deep infection after joint arthroplasty. Clin Orthop Relat Res. 2009; 467(7): 1859-1867.

112. Brahmbhatt RD, Huebner M, Scow JS, et al: National practice patterns in preoperative and postoperative antibiotic prophylaxis in breast procedures requiring drains: survey of the American Society of Breast Surgeons. Ann Surg Oncol. 2012; 19(10): 3205-3211.

113. Phillips BT, Wang ED, Mirrer J, et al: Current practice among plastic surgeons of antibiotic prophylaxis and closed-suction drains in breast reconstruction: experience, evidence, and implications for postoperative care. Ann Plast Surg. 2011; 66(5): 460-465.

114. Turano A: New clinical data on the prophylaxis of infections in abdominal, gynecologic, and urologic surgery. Multicenter Study Group. Am J Surg. 1992; 164(4A Suppl): 16S-20S.

115. Niederhauser U, Vogt M, Vogt P, Genoni M, Kunzli A, Turina MI: Cardiac surgery in a high-risk group of patients: is prolonged postoperative antibiotic prophylaxis effective? J Thorac Cardiovasc Surg. 1997; 114(2): 162-168.

116. Wymenga AB, Hekster YA, Theeuwes A, Muytjens HL, van Horn JR, Slooff TJ: Antibiotic use after cefuroxime prophylaxis in hip and knee joint replacement. Clin Pharmacol Ther. 1991; 50(2): 215-220.

117. McDonald M, Grabsch E, Marshall C, Forbes A: Single versus multiple-dose antimicrobial prophylaxis for major surgery: a systematic review. Aust N Z J Surg. 1998; 68(6): 388-396.

118. Heydemann JS, Nelson CL: Short-term preventive antibiotics. Clin Orthop Relat Res. 1986(205): 184-187.

119. Stone HH, Haney BB, Kolb LD, Geheber CE, Hooper CA. Prophylactic and preventive antibiotic therapy: timing, duration and economics. Ann Surg. 1979; 189(6): 691-699.

120. Williams DN, Gustilo RB: The use of preventive antibiotics in orthopaedic surgery. Clin Orthop Relat Res. 1984(190): 83-88.

121. Tang WM, Chiu KY, Ng TP, Yau WP, Ching PT, Seto WH: Efficacy of a single dose of cefazolin as a prophylactic antibiotic in primary arthroplasty. J Arthroplasty. 2003; 18(6): 714-718.

122. Bengston S, Knutson K, Lidgren L: Treatment of infected knee arthroplasty. Clin Orthop Relat Res. 1989(245): 173-178.

123. Sharma D, Douglas J, Coulter C, Weinrauch P, Crawford R: Microbiology of infected arthroplasty: implications for empiric peri-operative antibiotics. J Orthop Surg (Hong Kong). 2008; 16(3): 339-342.

124. Nickinson RS, Board TN, Gambhir AK, Porter ML, Kay PR: The microbiology of the infected knee arthroplasty. Int Orthop. 2010; 34(4): 505-510.

125. Peersman G, Laskin R, Davis J, Peterson M: Infection in total knee replacement: a retrospective review of 6489 total knee replacements. Clin Orthop Relat Res. 2001(392): 15-23.

126. Mont MA, Waldman BJ, Hungerford DS: Evaluation of preoperative cultures before second-stage reimplantation of a total knee prosthesis complicated by infection. A comparison-group study. J Bone Joint Surg Am. 2000; 82-A(11): 1552-1557.

127. Rafiq I, Gambhir AK, Wroblewski BM, Kay PR: The microbiology of infected hip arthroplasty. Int Orthop. 2006; 30(6): 532-535.

128. Al-Maiyah M, Hill D, Bajwa A, et al: Bacterial contaminants and antibiotic prophylaxis in total hip arthroplasty. J Bone Joint Surg Br. 2005; 87(9): 1256-1258.

129. Phillips JE, Crane TP, Noy M, Elliott TS, Grimer RJ: The incidence of deep prosthetic infections in a specialist orthopaedic hospital: a 15-year prospective survey. J Bone Joint Surg Br. 2006; 88(7): 943-948.

130. Tsukayama DT, Estrada R, Gustilo RB: Infection after total hip arthroplasty. A study of the treatment of one hundred and six infections. J Bone Joint Surg Am. 1996; 78(4): 512-523.

131. Moran E, Masters S, Berendt AR, McLardy-Smith P, Byren I, Atkins BL: Guiding empirical antibiotic therapy in orthopaedics: The microbiology of prosthetic joint infection managed by debridement, irrigation and prosthesis retention. J Infect. 2007; 55(1): 1-7.

132. Azzam K, McHale K, Austin M, Purtill JJ, Parvizi J: Outcome of a second two-stage reimplantation for periprosthetic knee infection. Clin Orthop Relat Res. 2009; 467(7): 1706-1714.

133. Kalra KP, Lin KK, Bozic KJ, Ries MD: Repeat 2-stage revision for recurrent infection of total hip arthroplasty. J Arthroplasty. 2010; 25(6): 880-884.

134. Jamsen E, Stogiannidis I, Malmivaara A, Pajamaki J, Puolakka T, Konttinen YT: Outcome of prosthesis exchange for infected knee arthroplasty: the effect of treatment approach. Acta Orthop. 2009; 80(1): 67-77.

135. Kubista B, Hartzler RU, Wood CM, Osmon DR, Hanssen AD, Lewallen DG: Reinfection after two-stage revision for periprosthetic infection of total knee arthroplasty. Int Orthop. 2012; 36(1): 65-71.

136. Mortazavi SM, O’Neil JT, Zmistowski B, Parvizi J, Purtill JJ: Repeat 2-stage exchange for infected total hip arthroplasty: a viable option? J Arthroplasty. 2012; 27(6): 923-926 e921.

137. Fletcher N, Sofianos D, Berkes MB, Obremskey WT: Prevention of perioperative infection. J Bone Joint Surg Am. 2007; 89(7): 1605-1618.

138. Dellinger EP, Gross PA, Barrett TL, et al: Quality standard for antimicrobial prophylaxis in surgical procedures. The Infectious Diseases Society of America. Infect Control Hosp Epidemiol. 1994; 15(3): 182-188.

139. Scher KS: Studies on the duration of antibiotic administration for surgical prophylaxis. Am Surg. 1997; 63(1): 59-62.

140. Shapiro M, Munoz A, Tager IB, Schoenbaum SC, Polk BF: Risk factors for infection at the operative site after abdominal or vaginal hysterectomy. N Engl J Med. 1982; 307(27): 1661-1666.

141. Polk HC, Jr, Trachtenberg L, Finn MP: Antibiotic activity in surgical incisions. The basis of prophylaxis in selected operations. JAMA. 19 1980; 244(12): 1353-1354.

142. Ohge H, Takesue Y, Yokoyama T, et al: An additional dose of cefazolin for intraoperative prophylaxis. Surg Today. 1999; 29(12): 1233-1236.

143. Morita S, Nishisho I, Nomura T, et al: The significance of the intraoperative repeated dosing of antimicrobials for preventing surgical wound infection in colorectal surgery. Surg Today. 2005; 35(9): 732-738.

144. Swoboda SM, Merz C, Kostuik J, Trentler B, Lipsett PA: Does intraoperative blood loss affect antibiotic serum and tissue concentrations? Arch Surg. 1996; 131(11): 1165-1171; discussion 1171-1162.

145. Markantonis SL, Kostopanagiotou G, Panidis D, Smirniotis V, Voros D: Effects of blood loss and fluid volume replacement on serum and tissue gentamicin concentrations during colorectal surgery. Clin Ther. 2004; 26(2): 271-281.

146. Klekamp JW, DiPersio D, Haas DW: No influence of large volume blood loss on serum vancomycin concentrations during orthopedic procedures. Acta Orthop Scand. 1999; 70(1): 47-50.

147. Meter JJ, Polly DW, Jr, Brueckner RP, Tenuta JJ, Asplund L, Hopkinson WJ: Effect of intraoperative blood loss on the serum level of cefazolin in patients managed with total hip arthroplasty. A prospective, controlled study. J Bone Joint Surg Am. 1996; 78(8): 1201-1205.

148. Polly DW, Jr, Meter JJ, Brueckner R, Asplund L, van Dam BE: The effect of intraoperative blood loss on serum cefazolin level in patients undergoing instrumented spinal fusion. A prospective, controlled study. Spine (Phila Pa 1976). 1996; 21(20): 2363-2367.

149. Moellering RC (Editor), Eliopoulos GM: The Sanford guide to antimicrobial therapy. 30th ed. Sandford Guides; 2000.

150. Leader WG, Tsubaki T, Chandler MH: Creatinine-clearance estimates for predicting gentamicin pharmacokinetic values in obese patients. Am J Hosp Pharm. 1994; 51(17): 2125-2130.

151. Janson B, Thursky K: Dosing of antibiotics in obesity. Curr Opin Infect Dis. 2012; 25(6): 634-649.

152. Begg EJ, Barclay ML, Duffull SB: A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol. 1995; 39(6): 605-609.

153. Truong J, Levkovich BJ, Padiglione AA: Simple approach to improving vancomycin dosing in intensive care: a standardised loading dose results in earlier therapeIAUc levels. Intern Med J. 2012; 42(1): 23-29.

154. Ho VP, Nicolau DP, Dakin GF, et al: Cefazolin dosing for surgical prophylaxis in morbidly obese patients. Surg Infect (Larchmt). 2012; 13(1): 33-37.

155. Wurtz R, Itokazu G, Rodvold K: Antimicrobial dosing in obese patients. Clin Infect Dis. 1997; 25(1): 112-118.

156. Rybak MJ, Lomaestro BM, Rotschafer JC, et al: Vancomycin therapeIAUc guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis. 2009; 49(3): 325-327.

157. Traynor AM, Nafziger AN, Bertino JS, Jr: Aminoglycoside dosing weight correction factors for patients of various body sizes. Antimicrob Agents Chemother. 1995; 39(2): 545-548.

158. van Kralingen S, Taks M, Diepstraten J, et al: Pharmacokinetics and protein binding of cefazolin in morbidly obese patients. Eur J Clin Pharmacol. 2011; 67(10): 985-992.

159. Edmiston CE, Krepel C, Kelly H, et al: Perioperative antibiotic prophylaxis in the gastric bypass patient: do we achieve therapeIAUc levels? Surgery. 2004; 136(4): 738-747.

160. Liu C: The bundled approach to MRSA surgical site infection prevention: is the whole greater than the sum of its parts? comment on “Sustained reduction in methicillin-resistant Staphylococcus aureus wound infections after cardiothoracic surgery”. Arch Intern Med. 2011; 171(1): 73-74.

161. Pofahl WE, Goettler CE, Ramsey KM, Cochran MK, Nobles DL, Rotondo MF: Active surveillance screening of MRSA and eradication of the carrier state decreases surgical-site infections caused by MRSA. J Am Coll Surg. 2009; 208(5): 981-986; discussion 986-988.

162. Wirganowicz PZ, Eckardt JJ, Dorey FJ, Eilber FR, Kabo JM: Etiology and results of tumor endoprosthesis revision surgery in 64 patients. Clin Orthop Relat Res. 1999(358): 64-74.

163. Safran MR, Kody MH, Namba RS, et al: 151 endoprosthetic reconstructions for patients with primary tumors involving bone. Contemp Orthop. 1994; 29(1): 15-25.

164. Malawer MM, Chou LB: Prosthetic survival and clinical results with use of large-segment replacements in the treatment of high-grade bone sarcomas. J Bone Joint Surg Am. 1995; 77(8): 1154-1165.

165. Capanna R, Morris HG, Campanacci D, Del Ben M, Campanacci M: Modular uncemented prosthetic reconstruction after resection of tumours of the distal femur. J Bone Joint Surg Br. 1994; 76(2): 178-186.

166. Mittermayer F, Krepler P, Dominkus M, et al: Long-term followup of uncemented tumor endoprostheses for the lower extremity. Clin Orthop Relat Res. 2001(388): 167-177.

167. Ghert M, Deheshi B, Holt G, et al: Prophylactic antibiotic regimens in tumour surgery (PARITY): protocol for a multicentre randomized controlled study. BMJ Open. 2012; 2(6).

168. Jansen B, Rinck M, Wolbring P, Strohmeier A, Jahns T: In vitro evaluation of the antimicrobial efficacy and biocompatibility of a silver-coated central venous catheter. J Biomater Appl. 1994; 9(1): 55-70.

169. Karchmer TB, Giannetta ET, Muto CA, Strain BA, Farr BM. A randomized crossover study of silver-coated urinary catheters in hospitalized patients. Arch Intern Med. 2000; 160(21): 3294-3298.

170. Tsuchiya H, Shirai T, Nishida H: New implant technology: iodine-coating for infection control. Paper presented at: 26th European Musculoskeletal Oncology Society Meeting, 2013; Gothenburg, Sweden.

171. Tsuchiya H, Shirai T, Nishida H, et al: Innovative antimicrobial coating of titanium implants with iodine. J Orthop Sci. 2012; 17(5): 595-604.

172. Hardes J, von Eiff C, Streitbuerger A, et al: Reduction of periprosthetic infection with silver-coated megaprostheses in patients with bone sarcoma. J Surg Oncol. 2010; 101(5): 389-395.

173. Gosheger G, Hardes J, Ahrens H, et al: Silver-coated megaendoprostheses in a rabbit model--an analysis of the infection rate and toxicological side effects. Biomaterials. 2004; 25(24): 5547-5556.

174. Buttaro MA, Gimenez MI, Greco G, Barcan L, Piccaluga F: High active local levels of vancomycin without nephrotoxicity released from impacted bone allografts in 20 revision hip arthroplasties. Acta Orthop. 2005; 76(3): 336-340.

175. Gosheger G, Goetze C, Hardes J, Joosten U, Winkelmann W, von Eiff C: The influence of the alloy of megaprostheses on infection rate. J Arthroplasty. 2008; 23(6): 916-920.

176. Witso E, Persen L, Benum P, Aamodt A, Husby OS, Bergh K: High local concentrations without systemic adverse effects after impaction of netilmicin-impregnated bone. Acta Orthop Scand. 2004; 75(3): 339-346.

177. Buttaro MA, Pusso R, Piccaluga F: Vancomycin-supplemented impacted bone allografts in infected hip arthroplasty. Two-stage revision results. J Bone Joint Surg Br. 2005; 87(3): 314-319.

178. Michalak KA, Khoo PP, Yates PJ, Day RE, Wood DJ: Iontophoresed segmental allografts in revision arthroplasty for infection. J Bone Joint Surg Br. 2006; 88(11): 1430-1437.

179. Khoo PP, Michalak KA, Yates PJ, Megson SM, Day RE, Wood DJ: Iontophoresis of antibiotics into segmental allografts. J Bone Joint Surg Br. 2006; 88(9): 1149-1157.

180. Winkler H, Stoiber A, Kaudela K, Winter F, Menschik F: One stage uncemented revision of infected total hip replacement using cancellous allograft bone impregnated with antibiotics. J Bone Joint Surg Br. 2008; 90(12): 1580-1584.

181. Buttaro MA, Guala AJ, Comba F, Suarez F, Piccaluga F: Incidence of deep infection in aseptic revision THA using vancomycin-impregnated impacted bone allograft. Hip Int. 2010; 20(4): 535-541.

182. Witso E, Persen L, Loseth K, Bergh K: Adsorption and release of antibiotics from morselized cancellous bone. In vitro studies of 8 antibiotics. Acta Orthop Scand. 1999; 70(3): 298-304.

183. Buttaro MA, Gonzalez Della Valle AM, Pineiro L, Mocetti E, Morandi AA, Piccaluga F: Incorporation of vancomycin-supplemented bone incorporation of vancomycin-supplemented bone allografts: radiographical, histopathological and immunohistochemical study in pigs. Acta Orthop Scand. 2003; 74(5): 505-513.

184. Witso E, Persen L, Loseth K, Benum P, Bergh K: Cancellous bone as an antibiotic carrier. Acta Orthop Scand. 2000; 71(1): 80-84.

185. Berbari EF, Hanssen AD, Duffy MC, et al: Risk factors for prosthetic joint infection: case-control study. Clin Infect Dis. 1998; 27(5): 1247-1254.

186. Yang K, Yeo SJ, Lee BP, Lo NN: Total knee arthroplasty in diabetic patients: a study of 109 consecutive cases. J Arthroplasty. 2001; 16(1): 102-106.

187. Meding JB, Reddleman K, Keating ME, et al: Total knee replacement in patients with diabetes mellitus. Clin Orthop Relat Res. 2003(416): 208-216.

188. Pedersen AB, Mehnert F, Johnsen SP, Sorensen HT: Risk of revision of a total hip replacement in patients with diabetes mellitus: a population-based follow up study. J Bone Joint Surg Br. 2010; 92(7): 929-934.

189. Adams AL, Paxton EW, Wang JQ, et al: Surgical outcomes of total knee replacement according to diabetes status and glycemic control, 2001 to 2009. J Bone Joint Surg Am. 20 2013; 95(6): 481-487.

190. Haverkamp D, Klinkenbijl MN, Somford MP, Albers GH, van der Vis HM: Obesity in total hip arthroplasty--does it really matter? A meta-analysis. Acta Orthop. 2011; 82(4): 417-422.

191. Namba RS, Paxton L, Fithian DC, Stone ML: Obesity and perioperative morbidity in total hip and total knee arthroplasty patients. J Arthroplasty. 2005; 20(7 Suppl 3): 46-50.

192. Dowsey MM, Choong PF: Early outcomes and complications following joint arthroplasty in obese patients: a review of the published reports. ANZ J Surg. 2008; 78(6): 439-444.

193. Parvizi J, Sullivan TA, Pagnano MW, Trousdale RT, Bolander ME: Total joint arthroplasty in human immunodeficiency virus-positive patients: an alarming rate of early failure. J Arthroplasty. 2003; 18(3): 259-264.

194. Ragni MV, Crossett LS, Herndon JH: Postoperative infection following orthopaedic surgery in human immunodeficiency virus-infected hemophiliacs with CD4 counts < or = 200/mm3. J Arthroplasty. 1995; 10(6): 716-721.

195. Habermann B, Eberhardt C, Kurth AA: Total joint replacement in HIV positive patients. J Infect. 2008; 57(1): 41-46.

196. Wang TI, Chen CF, Chen WM, et al: Joint replacement in human immunodeficiency virus-infected patients. J Chin Med Assoc. 2012; 75(11): 595-599.

197. Unger AS, Kessler CM, Lewis RJ: Total knee arthroplasty in human immunodeficiency virus-infected hemophiliacs. J Arthroplasty. 1995; 10(4): 448-452.

198. Silva M, Luck JV, Jr: Long-term results of primary total knee replacement in patients with hemophilia. J Bone Joint Surg Am. 2005; 87(1): 85-91.

199. Rodriguez-Merchan EC: Total knee replacement in haemophilic arthropathy. J Bone Joint Surg Br. 2007; 89(2): 186-188.

200. Shaarani SR, Collins D, O’Byrne JM: The need for guidelines in asplenic patients undergoing total joint arthroplasty: a case report. Case Rep Orthop. 2012; 2012: 147042.

201. Pour AE, Matar WY, Jafari SM, Purtill JJ, Austin MS, Parvizi J: Total joint arthroplasty in patients with hepatitis C. J Bone Joint Surg Am. 2011; 93(15): 1448-1454.

202. Orozco F, Post ZD, Baxi O, Miller A, Ong A: Fibrosis in hepatitis c patients predicts complications after elective total joint arthroplasty. J Arthroplasty. 2014; 29(1): 7-10. doi: 10.1016/j.arth.2013.03.023. Epub 2013, May 4.

203. McCleery MA, Leach WJ, Norwood T: Rates of infection and revision in patients with renal disease undergoing total knee replacement in Scotland. J Bone Joint Surg Br. 2010; 92(11): 1535-1539.

204. Lieberman JR, Fuchs MD, Haas SB, et al: Hip arthroplasty in patients with chronic renal failure. J Arthroplasty. 1995; 10(2): 191-195.

205. Sakalkale DP, Hozack WJ, Rothman RH: Total hip arthroplasty in patients on long-term renal dialysis. J Arthroplasty. 1999; 14(5): 571-575.

206. Li WC, Shih CH, Ueng SW, Shih HN, Lee MS, Hsieh PH: Uncemented total hip arthroplasty in chronic hemodialysis patients. Acta Orthop. 2010; 81(2): 178-182.

207. Nagoya S, Nagao M, Takada J, Kuwabara H, Kaya M, Yamashita T: Efficacy of cementless total hip arthroplasty in patients on long-term hemodialysis. J Arthroplasty. 2005; 20(1): 66-71.

208. Vergidis P, Lesnick TG, Kremers WK, Razonable RR: Prosthetic joint infection in solid organ transplant recipients: a retrospective case-control study. Transpl Infect Dis. 2012; 14(4): 380-386.

209. Tannenbaum DA, Matthews LS, Grady-Benson JC: Infection around joint replacements in patients who have a renal or liver transplantation. J Bone Joint Surg Am. 1997; 79(1): 36-43.

210. Mortazavi SM, Molligan J, Austin MS, Purtill JJ, Hozack WJ, Parvizi J: Failure following revision total knee arthroplasty: infection is the major cause. Int Orthop. 2011; 35(8): 1157-1164.

211. Poss R, Thornhill TS, Ewald FC, Thomas WH, Batte NJ, Sledge CB: Factors influencing the incidence and outcome of infection following total joint arthroplasty. Clin Orthop Relat Res. 1984(182): 117-126.

212. Sierra RJ, Cooney WPt, Pagnano MW, Trousdale RT, Rand JA: Reoperations after 3200 revision TKAs: rates, etiology, and lessons learned. Clin Orthop Relat Res. 2004(425): 200-206.

213. Liu C, Kakis A, Nichols A, Ries MD, Vail TP, Bozic KJ: Targeted use of vancomycin as perioperative prophylaxis reduces periprosthetic joint infection in revision TKA. Clin Orthop Relat Res. 2013. Epub before print.

214. Cuzon G, Naas T, Demachy MC, Nordmann P: Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in Klebsiella pneumoniae isolate from Greece. Antimicrob Agents Chemother. 2008; 52(2): 796-797.

215. Nordmann P, Cuzon G, Naas T: The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis. 2009; 9(4): 228-236.

216. Queenan AM, Bush K: Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev. 2007; 20(3): 440-458, table of contents.

217. Schwaber MJ, Carmeli Y: Carbapenem-resistant enterobacteriaceae: a potential threat. JAMA. 2008; 300(24): 2911-2913.

218. Bratu S, Landman D, Haag R, et al: Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med. 2005; 165(12): 1430-1435.

219. Marchaim D, Navon-Venezia S, Schwaber MJ, Carmeli Y: Isolation of imipenem-resistant Enterobacter species: emergence of KPC-2 carbapenemase, molecular characterization, epidemiology, and outcomes. Antimicrob Agents Chemother. 2008; 52(4): 1413-1418.

220. de Smet AM, Kluytmans JA, Cooper BS, et al: Decontamination of the digestive tract and oropharynx in ICU patients. N Engl J Med. 2009; 360(1): 20-31.

221. Pérez F, Pultz MJ, Endimiani A, Bonomo RA, Donskey CJ: Effect of antibiotic treatment on establishment and elimination of intestinal colonization by KPC-producing Klebsiella pneumoniae in mice. Antimicrob Agents Chemother. 2011; 55(6): 2585-2589.